13F Holdings
中文EN

EVO Evotec SE IFRS Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1412558 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY2.0%
TTM net income YoY-133.7%
TTM EPS YoY-136.2%
Revenue 3-yr CAGR8.8%
Net income 3-yr CAGR—

Margins

Gross margin14.4%
Operating margin-17.9%
Net margin-24.6%
FCF margin-12.5%
EBITDA margin-5.1%

Returns

ROE-18.9%
ROA-9.4%
ROIC (approx.)-17.9%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets50.2%
Debt / equity0.00x
Current ratio1.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.09x
Accruals ratio-10.3%
Payout ratio—
Capex / revenue14.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: EUR FY2024*2024-12-31FY2023*2023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue796.97M781.43M751.45M618.03M500.92M
Cost of revenue682.09M606.38M577.38M466.49M375.18M
Gross profit114.88M175.05M174.06M151.54M125.74M
R&D expense50.86M68.53M76.64M72.20M63.95M
SG&A expense188.20M169.61M156.19M105.44M77.20M
Operating income-142.52M-47.51M20.85M41.00M48.56M
Interest expense——13.15M9.25M8.46M
Pretax income-193.98M-80.59M-153.96M236.98M25.84M
Income tax2.10M3.32M21.70M21.47M19.56M
Net income-196.08M-83.91M-175.66M215.51M6.28M
EBITDA-40.90M45.47M104.05M111.39M—
EPS (basic)-1.11-0.47-0.991.300.04
EPS (diluted)-1.11-0.47-0.991.300.04
Balance sheet
Cash & equivalents306.39M510.91M415.15M699.33M422.58M
Short-term investments90.41M93.20M303.33M158.91M59.35M
Receivables116.32M98.40M171.80M132.08M79.00M
Inventory31.12M30.89M29.82M25.79M13.59M
Current assets681.96M903.16M1.07B1.10B658.84M
PP&E, netmay include right-of-use assets (IFRS)823.94M806.56M650.20M484.60M337.30M
Goodwill282.85M275.63M274.82M257.57M247.37M
Intangibles26.44M15.45M23.82M30.85M98.04M
Total assets1.91B2.25B2.26B2.24B1.46B
Current liabilities344.58M464.57M337.71M324.52M208.46M
Short-term debt27.11M129.97M1.56M36.14M15.39M
Long-term debt——328.30M326.34M331.02M
Total debt——329.85M362.48M346.41M
Total liabilities959.98M1.13B1.07B857.48M737.88M
Shareholders' equity952.52M1.12B1.19B1.38B724.46M
Net debt——-85.30M-336.85M-76.17M
Shares outstanding177.55M177.19M176.95M176.61M163.91M
Cash flow statement
Operating cash flow18.22M36.44M205.81M126.60M44.72M
Capital expenditure117.47M213.32M181.35M118.94M99.07M
Free cash flow-99.25M-176.88M24.46M7.66M-54.35M
Investing cash flow-71.19M-13.29M-412.80M-242.79M-155.09M
Financing cash flow-161.42M71.96M-58.15M393.01M246.41M
Depreciation & amortization101.62M92.98M83.20M70.40M—
Stock-based compensation5.04M9.63M9.92M7.80M5.29M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.